Roche drops partnership on depression treatment; Celldex shares slump on $30M fundraising; Prepping for the zombie apocalypse;

@FierceBiotech: Canaan cashing in on Shire's $750M deal for Advanced BioHealing. Item | Follow @FierceBiotech

@JohnCFierce: Another interesting point: "More than 90 percent of recently approved cancer drugs cost more than $20,000 for a 12-week course of therapy. Follow @JohnCFierce

> Roche says it is dropping out of its depression drug development pact with Germany's Evotec after researchers found that they couldn't recruit enough subjects for a Phase II study. Evotec says it will hunt for a new partner for EVT101. Report

> Celldex shares took a hit after the company unveiled plans to raise close to $30 million through a stock sale.  The money will be used to fund a late-stage study of its glioblastoma treatment. Report

> Enzon Pharmaceuticals today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study. Release

> Scientists in Australia and China are joining forces on a new genetics research program. Their work is designed to help discover a new generation of personalized treatments. Story

Pharma News

@FiercePharma: Generics, emerging markets to take over pharma growth. Story | Follow @FiercePharma

> J&J on trial for lack of warnings on kids' drugs. Report

> Pharmacies say goodbye to Avandia in November. News

> Cancer drug spending to leap at least 34%. Story

> Takeda snaps up Nycomed in $13.6B deal. Piece

Vaccines News

> Chongqing bids $93M for Bilthoven. Story 

> Cancer vaccine market to hit $7B by 2015. Report

> Study: HPV vax important for men. Item 

> Sanofi plots 2014 launch of new dengue vaccine. Story

> Celiac disease vax has positive Ph1 results. Article

Manufacturing News

> Golden State warning cites repeat violation. Article

> Particle detection pits man against machine. News

> Packager Amcor hears dual sustainability calls. Story 

> Pfizer's Viagra faces more counterfeit, generic attacks. News

> How GSK rose from a lonely, inventive shepherd. Report

And Finally...The CDC has issued some handy guidelines on preparing for the zombie apocalypse. And now that they have your attention they wouldn't mind if everyone in the U.S. followed the same general outline for any possible outbreak that could be headed our way. Story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.